CHIKV VLP vaccine + Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Chikungunya Virus

Conditions

Chikungunya Virus

Trial Timeline

May 1, 2026 → May 1, 2030

NCT ID

NCT07467707

About CHIKV VLP vaccine + Placebo

CHIKV VLP vaccine + Placebo is a phase 3 stage product being developed by Bavarian Nordic for Chikungunya Virus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07467707. Target conditions include Chikungunya Virus.

What happened to similar drugs?

0 of 10 similar drugs in Chikungunya Virus were approved

Approved (0) Terminated (2) Active (8)

🔄CHIKV VLP vaccine booster + Placebo boosterBavarian NordicPhase 3

🔄CHIKV VLP/adjuvant + PlaceboBavarian NordicPhase 3

🔄CHIKV VLP vaccine + PlaceboBavarian NordicPhase 3

❌VLA1553Valneva SEPhase 3

🔄Biological Vaccine VLA1553Valneva SEPhase 3

🔄Active + PlaceboValneva SEPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07467707	Phase 3	Recruiting	May 1, 2026	May 1, 2030	Chikungunya Virus
NCT07003984	Phase 3	Recruiting	Jun 5, 2025	Dec 1, 2028	Chikungunya Virus

Competing Products

20 competing products in Chikungunya Virus

See all competitors

Product	Company	Stage	Hype Score
VAL-181388	Moderna	Phase 1	0
mRNA-1944	Moderna	Phase 1	0
CHIKV VLP/unadjuvanted + CHIKV VLP/adjuvanted + Placebo	Bavarian Nordic	Phase 2	32
Chikungunya	Bavarian Nordic	Phase 2	32
CHIKV VLP vaccine booster + Placebo booster	Bavarian Nordic	Phase 3	41
CHIKV VLP/adjuvant + Placebo	Bavarian Nordic	Phase 3	37
CHIKV VLP, adjuvanted	Bavarian Nordic	Phase 2	32
CHIKV VLP/adjuvant + Placebo	Bavarian Nordic	Phase 3	37
CHIKV VLP vaccine + Placebo	Bavarian Nordic	Phase 3	44
Live-attenuated CHIKV vaccine VLA1553	Valneva SE	Pre-clinical	27
VLA1553	Valneva SE	Phase 3	26
Live-attenuated CHIKV vaccine VLA1553	Valneva SE	Pre-clinical	24
Biological Vaccine VLA1553	Valneva SE	Phase 3	34
VLA1553 full dose + VLA1553 half dose + Control	Valneva SE	Phase 2	29
Active + Placebo	Valneva SE	Phase 3	34
Live-attenuated CHIKV vaccine VLA1553 + Vaccine(s) approved for use during pregnancy by the MoH	Valneva SE	Pre-clinical	27
VLA1553	Valneva SE	Phase 3	38
VLA1553 + Control	Valneva SE	Phase 3	26
VLA1553 + Placebo	Valneva SE	Phase 3	34
VLA1553	Valneva SE	Phase 1	23